Equillium, Inc. (NASDAQ:EQ) Stock Has Consensus Target Price of $7.57

Key Points

• Equillium has a “Moderate Buy” consensus from 11 analysts, with seven buy ratings, two strong-buy ratings, one hold and one sell. The average 12-month price target is $7.57, including targets of $12 from Roth Capital and $6 from Leerink Partners.
• Institutional investors own 27.05% of Equillium, with Jupiter Topco making the largest reported purchase during the second quarter, acquiring a stake valued at approximately $20.7 million.
• Shares opened at $1.23, well below the 50-day and 200-day moving averages of $1.86 and $2.25, respectively. Equillium reported quarterly EPS of negative $0.04, beating estimates by $0.01, while analysts expect a full-year loss of $0.21 per share.

Shares of Equillium, Inc. (NASDAQ:EQ - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the eleven ratings firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and two have given a strong buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $7.57.

Several brokerages have recently issued reports on EQ. Weiss Ratings reiterated a "sell (d-)" rating on shares of Equillium in a research report on Monday, September 21st. Roth Capital reaffirmed a "buy" rating and set a $12.00 target price on shares of Equillium in a report on Friday, September 4th. Clear Str upgraded Equillium to a "strong-buy" rating in a research report on Tuesday, July 21st. Wall Street Zen lowered Equillium from a "hold" rating to a "sell" rating in a research note on Saturday, September 19th. Finally, Leerink Partners began coverage on shares of Equillium in a report on Monday, October 12th. They issued an "outperform" rating and a $6.00 price objective for the company.

Institutional Trading of Equillium

A number of large investors have recently made changes to their positions in the company. High Net Worth Advisory Group LLC purchased a new stake in shares of Equillium during the 2nd quarter worth approximately $107,000. Two Sigma Securities LLC purchased a new position in Equillium during the 2nd quarter worth approximately $35,000. Coastal Bridge Advisors LLC purchased a new stake in Equillium in the second quarter valued at approximately $48,000. Jefferies Financial Group Inc. purchased a new position in shares of Equillium during the second quarter worth approximately $109,000. Finally, Jupiter Topco LLC acquired a new stake in Equillium during the 2nd quarter worth $20,685,000. 27.05% of the stock is currently owned by hedge funds and other institutional investors.

Equillium Price Performance

Shares of NASDAQ:EQ opened at $1.23 on Friday. The business's 50-day moving average is $1.86 and its 200 day moving average is $2.25. Equillium has a 1 year low of $0.76 and a 1 year high of $3.54. The firm has a market capitalization of $77.99 million, a P/E ratio of -6.15 and a beta of 1.93.

Equillium (NASDAQ:EQ - Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.05) by $0.01. On average, analysts expect that Equillium will post -0.21 EPS for the current year.

Equillium Company Profile

Equillium, Inc is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory diseases. The company's approach centers on modulating immune pathways involved in disease progression, with the goal of addressing conditions that have limited treatment options.

Equillium's lead product candidate is itolizumab, a monoclonal antibody that targets CD6, an immune-cell receptor involved in the regulation of T-cell activity. The company is evaluating itolizumab in immune-mediated conditions, including acute graft-versus-host disease and lupus nephritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.